BRIEF published on 03/30/2026 at 22:16, 5 months 18 days ago Inventiva Announces 2025 Financial Results and Business Update Public Offering Cash Reserves Inventiva Lanifibranor 2025 Financial Results
PRESS RELEASE published on 03/30/2026 at 22:11, 5 months 18 days ago Inventiva reports 2025 full year results and provides a business update Inventiva reports 2025 full year results with €4.5 million revenues, provides business update on strategic pipeline, clinical trials, and financial performance Financial Performance Business Update Clinical Trials Inventiva 2025 Results
BRIEF published on 03/23/2026 at 22:05, 5 months 25 days ago Inventiva Announces Schedule for 2025 Financial Results Financial Results Conference Call Biopharmaceutical Inventiva MASH
BRIEF published on 03/23/2026 at 22:05, 5 months 25 days ago Inventiva announces its 2025 annual financial results Financial Results Conference Call Investors Steatohepatitis Oral Therapy
PRESS RELEASE published on 03/23/2026 at 22:00, 5 months 25 days ago Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results Inventiva to release 2025 full-year financial results on March 30, 2026, followed by a conference call on March 31, 2026. Details on the company's website Financial Results Conference Call Biopharmaceutical Inventiva Therapy
BRIEF published on 03/23/2026 at 09:51, 5 months 25 days ago JP Morgan Chase & Co. crosses ownership thresholds in INVENTIVA Actions Participation Threshold Crossing JP Morgan Inventiva
BRIEF published on 03/23/2026 at 09:50, 5 months 25 days ago Threshold crossings at INVENTIVA Shareholders Voting Rights Inventiva Threshold Crossings Shareholders' Agreement
BRIEF published on 03/16/2026 at 09:40, 6 months 1 day ago JP Morgan Chase reduces its stake in Inventiva Actions Participation Crossing Thresholds JP Morgan Inventiva
BRIEF published on 03/12/2026 at 15:56, 6 months 5 days ago Threshold Crossing at Inventiva Actions Stock Market Crossing Thresholds JP Morgan Chase & Co. Inventiva
BRIEF published on 02/17/2026 at 14:32, 7 months ago Threshold Crossing by Deep Track Biotechnology Voting Rights Actions Threshold Crossing Inventiva Deep Track
Published on 09/18/2026 at 00:55, 1 hour 21 minutes ago Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 00:25, 1 hour 51 minutes ago CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/17/2026 at 22:15, 4 hours 1 minute ago Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/17/2026 at 22:15, 4 hours 1 minute ago Vanta Attends 2026 All-In Summit in Los Angeles, a Leading Gathering of Business, Investment and Industry Leaders
Published on 09/17/2026 at 22:05, 4 hours 11 minutes ago Loop Industries Forms Strategic Alternatives Committee to Maximize Shareholder Value
Published on 09/17/2026 at 19:00, 7 hours 16 minutes ago Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Published on 09/17/2026 at 18:58, 7 hours 17 minutes ago EQS-Adhoc: H2APEX Group SCA: General Partner of H2APEX Group SCA resolves to prepare for the transfer of its stock exchange listing from the Regulated Market (Prime Standard) to the Scale segment of the Frankfur
Published on 09/17/2026 at 18:25, 7 hours 51 minutes ago Magentic raises $18M to build the AI workforce for the physical world
Published on 09/17/2026 at 18:10, 8 hours 6 minutes ago A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%
Published on 09/17/2026 at 17:46, 8 hours 30 minutes ago RBI categorically denies the allegations of short-seller report
Published on 09/17/2026 at 17:40, 8 hours 36 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 8 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 19 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
